Sorrento Therapeutics (SRNE) Reports Q3 Loss of $0.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts SRNE Hot Sheet
Join SI Premium – FREE
Sorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.03), versus ($0.27) reported last year. Revenue for the quarter came in at $1.1 million, versus $1.28 million reported last year.
For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransUnion (TRU) Tops Q3 EPS by 4c; Offers FY26 EPS Guidance
- Daqo New Energy (DQ) Tops Q3 EPS by 28c
- Ares Capital to acquire MidCap Financial in $2.6B stock-cash deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
